Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus

European Heart Journal

18 February 2022
Organised by: Logo
ESC Journals DISEASES OF THE AORTA, PERIPHERAL VASCULAR DISEASE, STROKE Stroke HEART FAILURE Chronic Heart Failure IMAGING Cardiac Computed Tomography (CT) Cardiac Magnetic Resonance (CMR) Echocardiography OTHER PREVENTIVE CARDIOLOGY Rehabilitation and Sports Cardiology Risk Factors and Prevention VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Pericardial Disease BASIC SCIENCE

Abstract

Abstract

Emerging as a new epidemic, long COVID or post-acute sequelae of coronavirus disease 2019 (COVID-19), a condition characterized by the persistence of COVID-19 symptoms beyond 3 months, is anticipated to substantially alter the lives of millions of people globally. Cardiopulmonary symptoms including chest pain, shortness of breath, fatigue, and autonomic manifestations such as postural orthostatic tachycardia are common and associated with significant disability, heightened anxiety, and public awareness. A range of cardiovascular (CV) abnormalities has been reported among patients beyond the acute phase and include myocardial inflammation, myocardial infarction, right ventricular dysfunction, and arrhythmias. Pathophysiological mechanisms for delayed complications are still poorly understood, with a dissociation seen between ongoing symptoms and objective measures of cardiopulmonary health. COVID-19 is anticipated to alter the long-term trajectory of many chronic cardiac diseases which are abundant in those at risk of severe disease. In this review, we discuss the definition of long COVID and its epidemiology, with an emphasis on cardiopulmonary symptoms. We further review the pathophysiological mechanisms underlying acute and chronic CV injury, the range of post-acute CV sequelae, and impact of COVID-19 on multiorgan health. We propose a possible model for referral of post-COVID-19 patients to cardiac services and discuss future directions including research priorities and clinical trials that are currently underway to evaluate the efficacy of treatment strategies for long COVID and associated CV sequelae.

Contributors

Betty Raman
Betty Raman

Author

University of Oxford Oxford , United Kingdom of Great Britain & Northern Ireland

Stefan Neubauer
Stefan Neubauer

Author

University of Oxford Oxford , United Kingdom of Great Britain & Northern Ireland